Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib vs Bevacizumab with Chemotherapy in 2nd-line Metastatic Colorectal Cancer
NCT05555901Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Jun 2023
- Primary completion
- Sep 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fruquintinib in metastatic colorectal cancer (mCRC), sponsored by Fudan University. Status: unknown.
02
Drugs
fruquintinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT05555901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05555901.